InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,277.51
(
0.80%
)
US TECH 100
18,064.80
(
0.02%
)
Dow Jones
38,686.32
(
1.51%
)
Brent Oil
81.30
(
0.00%
)
Bitcoin
67,752.40
(
0.40%
)
Post# of 158400
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Lewisinhk

Send PM Follow Ignore
Followers 12
Posts 170
Boards Moderated 0
Alias Born 11/08/2012

Lewisinhk

Re: None

Wednesday, 04/01/2015 4:23:54 AM

Wednesday, April 01, 2015 4:23:54 AM

Post# of 158400
Roche's vesanoid, for APL, currently the only differentiation based therapeutic on the market with FDA approval? Roche's 2014 acquisitions indicates strong IP expansion in this field...Diffron-C with Ichims two patented complementary novel molecules can prove even more effective against APL...what the heck is RGBP doing on the OTC, this science is worth hundreds of millions alone, if we were nasdaq this would be steadily increasing as the pipeline develops, one day the OTC will realize the value here
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up